Breaking News, Collaborations & Alliances

INOVIO, Coherus Enter Cancer Drug Combo Clinical Collaboration

To evaluate INO-3112 and LOQTORZI as a potential treatment for HPV16/18 positive throat cancer.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

INOVIO, a biotechnology company developing DNA medicines to help treat and protect people from HPV-associated diseases, entered a clinical collaboration and supply agreement with Coherus BioSciences, Inc. to evaluate the combination of INO-3112 and LOQTORZI (toripalimab-tpzi) as a potential treatment for locoregionally advanced, high-risk, HPV16/18 positive oropharyngeal squamous cell carcinoma (OPSCC), a type of head and neck cancer commonly known as throat cancer.   Coherus will provide LOQT...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters